Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Motesanib Diphosphate (AMG 706) 是一种有效的VEGFR1/2/3的 ATP 竞争性抑制剂,IC50值为 2 nM/3 nM/6 nM,与对 Kit 的选择性相似,是 PDGFR 和 Ret 的 10 倍多。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 377 | 现货 | ||
5 mg | ¥ 913 | 现货 | ||
10 mg | ¥ 1,580 | 现货 | ||
25 mg | ¥ 2,680 | 现货 | ||
50 mg | ¥ 3,920 | 现货 | ||
100 mg | ¥ 5,680 | 现货 | ||
500 mg | ¥ 11,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,130 | 现货 |
产品描述 | Motesanib Diphosphate (AMG 706) is the orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. |
靶点活性 | c-Kit:8 nM, VEGFR2/Flk1:6 nM, VEGFR1:2 nM, VEGFR3:6 nM, VEGFR2:3 nM |
体外活性 | 在大鼠角膜模型中,每天口服两次(ED50=2.1 mg/kg )或一次(ED50=4.9 mg/kg )Motesanib Diphosphate能够抑制血管内皮生长因子诱导的血管生成.在头部和颈部鳞状细胞癌移植瘤模型中,Motesanib Diphosphate和辐射治疗联用,显示出显著地抗癌活性. |
体内活性 | 在VEGF诱导的HUVECs细胞中(IC50 =10 nM),Motesanib Diphosphate 明显抑制细胞增殖。对于血小板衍生因子诱导的增殖(IC50=207 nM)和SCF诱导的c-kit磷酸化(IC50=37 nM),Motesanib Diphosphate能够显著抑制。人脐静脉内皮细胞,Motesanib Diphosphate增强细胞对于放射性的敏感程度。对人VEGFR家族,Motesanib Diphosphate具有广谱活性。 |
激酶实验 | In vitro kinase assays: Optimal enzyme, ATP, and substrate (gastrin peptide) concentrations are established for each enzyme using homogeneous time-resolved fluorescence (HTRF) assays. Motesanib Diphosphate is tested in a 10-point dose-response curve for each enzyme using an ATP concentration of two-thirds Km for each. Most assays consist of enzyme mixed with kinase reaction buffer [20 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 5 mM MnCl2, 100 mM NaCl, 1.5 mM EGTA]. A final concentration of 1 mM DTT, 0.2 mM NaVO4, and 20 μg/mL BSA is added before each assay. For all assays, 5.75 mg/mL streptavidin-allophycocyanin and 0.1125 nM Eu-PT66 are added immediately before the HTRF reaction. Plates are incubated for 30 minutes at room temperature and read on a Discovery instrument. IC50 values are calculated using the Levenberg-Marquardt algorithm into a four-parameter logistic equation. |
细胞实验 | Cells are preincubated for 2 hours with different concentrations of Motesanib Diphosphate, and exposed with 50 ng/mL VEGF or 20 ng/mL bFGF for an additional 72 hours. Cells are washed twice with DPBS, and plates are frozen at -70 °C for 24 hours. Proliferation is assessed by the addition of CyQuant dye, and plates are read on a Victor 1420 workstation. IC50 data are calculated using the Levenberg-Marquardt algorithm into a four-parameter logistic equatio(Only for Reference) |
别名 | Motesanib, AMG 706, 二磷酸莫替沙尼 |
分子量 | 569.44 |
分子式 | C22H23N5O·2H3PO4 |
CAS No. | 857876-30-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 16 mg/mL (28.1 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (163.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O / DMSO | 1 mM | 1.7561 mL | 8.7806 mL | 17.5611 mL | 43.9028 mL |
5 mM | 0.3512 mL | 1.7561 mL | 3.5122 mL | 8.7806 mL | |
10 mM | 0.1756 mL | 0.8781 mL | 1.7561 mL | 4.3903 mL | |
20 mM | 0.0878 mL | 0.439 mL | 0.8781 mL | 2.1951 mL | |
DMSO | 50 mM | 0.0351 mL | 0.1756 mL | 0.3512 mL | 0.8781 mL |
100 mM | 0.0176 mL | 0.0878 mL | 0.1756 mL | 0.439 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Motesanib Diphosphate 857876-30-3 Angiogenesis Tyrosine Kinase/Adaptors VEGFR c-Kit Motesanib AMG-706 inhibit AMG 706 Diphosphate Vascular endothelial growth factor receptor AMG706 SCFR Inhibitor AMG 706 CD117 二磷酸莫替沙尼 inhibitor